Search results
Remdesivir has no significant effect on patients with COVID-19 who are already being ventilated. Among other hospitalised patients, it has a small effect against death or progression to ventilation (or both).
From my high level reading and anecdotal experience on Reddit, it seems Paxlovid seems to be a better alternative, albeit it’s for outpatient care. Should I have my dad wait for a day until he can swallow so he can take Paxlovid or is Remdesivir good enough?
Najważniejsze informacje. • U dorosłych hospitalizowanych z powodu COVID-19, stosowanie remdesiwiru, w porównaniu z placebo (leczeniem pozorowanym) lub standardową opieką, ma prawdopodobnie niewielki lub żaden wpływ na ryzyko zgonu w ciągu 150 dni od rozpoczęcia leczenia.
22 gru 2021 · A 3-day course of remdesivir had an acceptable safety profile and prevented disease progression resulting in hospitalization among high-risk patients with Covid-19.
21 lut 2023 · This individual patient data meta-analysis showed that remdesivir reduced mortality in patients hospitalised with COVID-19 who required no or conventional oxygen support, but was underpowered to evaluate patients who were ventilated when receiving remdesivir.
21 maj 2022 · Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
14 wrz 2021 · The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial. We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with standard of care alone in patients admitted to hospital with COVID-19, with indication of oxygen or ventilator support. Methods.
